In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Outlook
2023

Annual Industry Ranking And Forecast

Generics And Biosimilars Industry Reshaped By Transformations

Annual Top 50 Sees Leading Firms Change Position And New Entrants Join

Executive Summary

The latest Generics Bulletin Top 50 ranking of global generics and biosimilars companies sees a new name in the top five amid transformations for some of the leading off-patent players. Meanwhile, a number of mid-level firms shift position and newcomers climb into the bottom of the table.

You may also be interested in...



European Off-Patent Industry Welcomes Unitary SPC Pre-Grant Opposition

European off-patent industry association Medicines for Europe has welcomed the European Parliament’s “balanced stand” on unitary SPC regulation after “safeguard” provisions allowing pre-grant opposition and explicitly banning patent linkage were adopted.

Biocon Stelara Settlement Places Firm Among Earlier US Rivals

Biocon Biologics has secured a launch date for its planned US biosimilar to Stelara that puts it ahead of some of the competition.

Alvotech Raises Further Funds After FDA Green Light

Alvotech has announced a share sale that will raise $166m for the biosimilars developer, in the wake of its recent US Food and Drug Administration approval for its AVT02 adalimumab biosimilar, Simlandi.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

IV146747

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel